ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John W.C. Entwistle, III
Melvyn Goldberg
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Entwistle, J. W.C.
Right arrow Articles by Goldberg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Entwistle, J. W.C., III
Right arrow Articles by Goldberg, M.
Related Collections
Right arrow Esophagus - cancer

Ann Thorac Surg 2002;73:1009-1015
© 2002 The Society of Thoracic Surgeons

Review

Multimodality therapy for resectable cancer of the thoracic esophagus

John W.C. Entwistle, III, MD, PhDa, Melvyn Goldberg, MD*a

a Department of Surgical Oncology, Division of Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

* Address reprint requests to Dr Goldberg, Division of Thoracic Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111 USA
e-mail: m_goldberg{at}fccc.edu

The frequency of esophageal carcinoma continues to increase in North America primarily because of the increased incidence of Barrett’s epithelium in the distal esophagus and its malignant potential. Aggressive treatments involving multimodality therapies have been offered to improve overall poor survival rates. A review of this experience follows, to explain the rationale and to compare results of therapies. Although preoperative chemoradiation therapy is commonly used for locally advanced disease, few data support its superiority over surgical resection alone, followed by adjuvant therapy when appropriate. Hence this regimen should be limited to patients enrolled in controlled, randomized studies until the data support its widespread use.




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
J. G. Gaca, R. P. Petersen, B. L. Peterson, D. H. Harpole Jr., T. A. D'Amico, T. N. Pappas, H. F. Seigler, W. G. Wolfe, and D. S. Tyler
Pathologic Nodal Status Predicts Disease-Free Survival After Neoadjuvant Chemoradiation for Gastroesophageal Junction Carcinoma
Ann. Surg. Oncol., March 1, 2006; 13(3): 340 - 346.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.